Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2015 Sep 2;14(11):2519–2526. doi: 10.1158/1535-7163.MCT-15-0383

Figure 4.

Figure 4

In vivo treatment of USPC-ARK-1 and USPC-ARK-2. Mice were treated with vehicle control (0.5% methylcellulose-0.2% Tween 80), neratinib (40 mg\kg), taselisib (10 mg\kg) or the combination for 60 days. Measurements are reported as mean ± SEM. Upper panel: Graph showing a statistically significant difference in tumor growth of USPC-ARK-1 between the control group and the treated groups. Lower panel: Graph showing a statistically significant difference in tumor growth of USPC-ARK-2 between the control group and the treated groups. The arrows denote the time point in which we started the combination treatment in single agent resistant mice